Tango reports pancreatic cancer combo data, plans Phase 3 start in 1H 2027
Tango Therapeutics said its vopimetostat-daraxonrasib combination hit an 82% response rate in pancreatic cancer and reported $977.5 million in cash as of September 30, 2026.
Tango Therapeutics reported on November 9, 2026 that in October 2026 it disclosed updated data on vopimetostat combined with Revolution Medicines' RAS(ON) inhibitors daraxonrasib or zoldonrasib in patients with MTAP-deleted, RAS-mutant pancreatic cancer, showing the daraxonrasib combination reached an 82% objective response rate and an 88% nine-month progression-free survival rate in efficacy-evaluable second- and third-line pancreatic ductal adenocarcinoma patients, with median PFS not yet reached.1 The company specified that efficacy-evaluable patients had received their first dose at least 14 weeks before the August 20, 2026 data cutoff, and the combination showed a generally well-tolerated safety profile at dose level one, consisting of vopimetostat 200 mg and daraxonrasib 100 mg once daily.1
Based on these results, Tango plans to start a pivotal Phase 3 study of vopimetostat plus daraxonrasib in front-line MTAP-deleted pancreatic cancer in the first half of 2027, designed as a global randomized trial comparing the combination at the same doses against standard-of-care chemotherapy, with dual primary endpoints of ORR and PFS and overall survival as a key secondary endpoint.1 Separately, the company intends to discuss with regulators the possibility of seeking approval of the combination in second-line PDAC.1
Other pipeline items: in November 2026 Tango began enrollment in a Phase 1/2 study combining vopimetostat with Erasca's pan-RAS molecular glue ERAS-0015 in MTAP-deleted pancreatic cancer and MTAP-deleted/RAS-mutant NSCLC.1 In October 2026 Tango also said it plans a roughly 25-patient Phase 1/2 study of vopimetostat with panRAS inhibitors in MTAP-wild type pancreatic cancer, starting in the first half of 2027.1 The company said in October 2026 it reprioritized research and development to focus on PRMT5-targeted therapies.1 Tango expects to disclose vopimetostat lung cancer monotherapy data and TNG456 data in lung cancer, glioblastoma and other cancers in January 2027.1
On finances, Tango said it held a cash position of $977.5 million as of September 30, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.